{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:51:16Z","timestamp":1753890676410,"version":"3.41.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background and aim<\/jats:title><jats:p>High-dose statin therapy before percutaneous coronary intervention (PCI) is thought to reduce the occurrence of Peri-procedural Myocardial Infarction (PPMI), which is associated with increased mortality and prolonged hospitalization, especially in statin na\u00efve patients. This study aims to investigate the effect of rosuvastatin loading dose on PPMI and major adverse cardiac and cerebrovascular events (MACCE) in patients undergoing elective PCI, considering their statin use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>One hundred sixty-five patients with stable coronary artery disease (CAD) without heart failure (HF) or chronic kidney disease (CKD) were included in the study. They were divided into two groups: patients already on statin treatment (<jats:italic>n<\/jats:italic>:126) and statin naive patients (<jats:italic>n<\/jats:italic>:39). Both groups were randomly assigned to high-dose (40\u2005mg) rosuvastatin (<jats:italic>n<\/jats:italic>:86) or a non- loading dose group (<jats:italic>n<\/jats:italic>:79). The primary endpoint was the incidence of PPMI, and the secondary endpoint was MACCE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean age of study population was 59\u2009\u00b1\u20099.4 years with 77% being male (<jats:italic>n<\/jats:italic>\u2009=\u2009127). The median follow-up (FU) time was 368 day. Thirty patients were diagnosed with PPMI after PCI (19 in the high-dose group and 11 in the no-loading-dose group). Meanwhile, less than half of study population (77 patients, 46.7%) had complex lesion type (B2, C) and 88 of those (53.3%) had simple lesion type (A, B1). PPMI was observed more frequently in statin-naive patients (23%) than in statin users (17%), although the difference was not statistically significant. Only two patients (1.2%) experienced MACCE during the FU period. One of these patients, who had a type C lesion, belonged to group A2 and underwent Target Vessel Revascularization (TVR) on the 391st day. The other patient, with a type B1 lesion, was in group A1 and was hospitalized due to Acute Coronary Syndrome (ACS) on the 40th day of FU.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Pre-procedural administration of high dose rosuvastatin in patients with stable coronary artery disease did not decrease PPMI, independent of chronic statin use.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1435989","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T05:08:59Z","timestamp":1724130539000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of preprocedural statin loading on clinical outcomes in patients undergoing elective percutaneous coronary intervention"],"prefix":"10.3389","volume":"11","author":[{"given":"Umit Yasar","family":"Sinan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengisu","family":"Keskin Meric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurbanu","family":"Bursa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gkiozde","family":"Moumin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysem","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alev","family":"Arat Ozkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/CRD.0b013e31826db7ff","article-title":"Statin loading before percutaneous coronary intervention to reduce periprocedural myocardial infarction","volume":"20","author":"Norris","year":"2012","journal-title":"Cardiol Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/ccd.26939","article-title":"Risk stratification of periprocedural myocardial infarction after percutaneous coronary intervention: analysis based on the SCAI definition","volume":"89","author":"Zhang","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"key":"B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1161\/CIRCINTERVENTIONS.108.765610","article-title":"Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients","volume":"1","author":"Prasad","year":"2008","journal-title":"Circ Cardiovasc Interv"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1093\/eurheartj\/eht048","article-title":"Frequency, causes, predictors, and clinical significance of peri-procedural myocardial infarction following percutaneous coronary intervention","volume":"34","author":"Park","year":"2013","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0735-1097(99)00298-3","article-title":"Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course: implications for early discharge after coronary intervention","volume":"34","author":"Kini","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0735-1097(00)00777-4","article-title":"Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: results in 7,472 octogenarians","volume":"36","author":"Batchelor","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S0002-9149(98)00347-6","article-title":"Effectiveness of percutaneous coronary interventions to prevent recurrent coronary events in patients on chronic hemodialysis","volume":"82","author":"Marso","year":"1998","journal-title":"Am J Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ijcard.2008.03.033","article-title":"The syntax score predicts peri-procedural myocardial necrosis during percutaneous coronary intervention","volume":"135","author":"van Gaal","year":"2009","journal-title":"Int J Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4103\/0971-9784.197796","article-title":"Pleiotropic effects of statins in the perioperative setting","volume":"20","author":"Galyfos","year":"2017","journal-title":"Ann Card Anaesth"},{"key":"B10","doi-asserted-by":"publisher","first-page":"E36","DOI":"10.1002\/ccd.24403","article-title":"Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial","volume":"81","author":"Sardella","year":"2013","journal-title":"Catheter Cardiovasc Interv"},{"key":"B11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S1567-5688(03)00004-7","article-title":"Comparative pharmacology of rosuvastatin","volume":"4","author":"McTaggart","year":"2013","journal-title":"Atheroscler"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth universal definition of myocardial infarction","volume":"138","author":"Thygesen","year":"2018","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/ccd.23270","article-title":"ACC\/AHA classification of coronary lesions reflects medical resource use in current percutaneous coronary interventions","volume":"80","author":"Sakakura","year":"2012","journal-title":"Catheter Cardiovasc Interv"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/eurheartj\/ehx799","article-title":"Periprocedural myocardial infarction and injury in elective coronary stenting","volume":"39","author":"Zeitouni","year":"2018","journal-title":"Eur Heart J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10557-010-6224-1","article-title":"Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin","volume":"24","author":"Cay","year":"2010","journal-title":"Cardiovasc Drugs Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1016\/j.jacc.2009.07.005","article-title":"Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction","volume":"54","author":"Briguori","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.amjcard.2009.04.048","article-title":"Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study","volume":"104","author":"Veselka","year":"2009","journal-title":"Am J Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jacc.2009.05.028","article-title":"Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (atorvastatin for reduction of myocardial damage during angioplasty) randomized trial","volume":"54","author":"Di Sciascio","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.ehj.2004.07.017","article-title":"Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction","volume":"25","author":"Briguori","year":"2004","journal-title":"Eur Heart J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1161\/01.CIR.0000137828.06205.87","article-title":"Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (atorvastatin for reduction of myocardial damage during angioplasty) study","volume":"110","author":"Pasceri","year":"2004","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.jacc.2007.02.025","article-title":"Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial","volume":"49","author":"Patti","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ijcard.2008.06.055","article-title":"The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome","volume":"137","author":"Yun","year":"2009","journal-title":"Int J Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.jacc.2006.06.061","article-title":"Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (atorvastatin for reduction of myocardial damage during angioplasty-cell adhesion molecules) substudy","volume":"48","author":"Patti","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/MCA.0b013e328341baee","article-title":"Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury","volume":"22","author":"Yu","year":"2011","journal-title":"Coron Artery Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1161\/01.CIR.0000037520.89770.5E","article-title":"Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction","volume":"106","author":"Herrmann","year":"2002","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1161\/CIRCOUTCOMES.111.960740","article-title":"Effectiveness of preprocedural statin therapy on clinical outcomes for patients with stable coronary artery disease after percutaneous coronary interventions","volume":"4","author":"Ko","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.amjcard.2013.02.018","article-title":"Usefulness of rosuvastatin to prevent periprocedural myocardial injury in patients undergoing elective coronary intervention","volume":"111","author":"Takano","year":"2013","journal-title":"Am J Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jcin.2009.11.021","article-title":"Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial","volume":"3","author":"Kim","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"B33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s43044-024-00481-7","article-title":"Efficacy of single high-dose statin before percutaneous coronary intervention in acute coronary syndrome: a systematic review and meta-analysis","volume":"76","author":"de Liyis","year":"2024","journal-title":"Egypt Heart J"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1435989\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T05:09:02Z","timestamp":1724130542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1435989\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":34,"alternative-id":["10.3389\/fcvm.2024.1435989"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1435989","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"article-number":"1435989"}}